FibroBiologics and Charles River link for chronic disease therapies manufacture

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.

Oct 22, 2024 - 04:00

FibroBiologics and Charles River link for chronic disease therapies manufacture

FibroBiologics has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies.

Read the original article

Tags:

Previous Article

ImmunoPrecise touts potential of rabbit monoclonal antibodies in oncology

FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Replimune kickstarts Phase III melanoma trial studying RP1 immunotherapy

Replimune kickstarts Phase III melanoma trial studying ...

Aug 15, 2024

Beta Bionics’ automated insulin delivery system picks up manufacturing partner

Beta Bionics’ automated insulin delivery system picks u...

May 26, 2023

Incyte gets grant for treatment of various cancers usin...

Apr 5, 2024